1. Home
  2. ALKT vs RAPP Comparison

ALKT vs RAPP Comparison

Compare ALKT & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alkami Technology Inc.

ALKT

Alkami Technology Inc.

HOLD

Current Price

$16.48

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$41.33

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALKT
RAPP
Founded
2007
2022
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
ALKT
RAPP
Price
$16.48
$41.33
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$28.57
$48.50
AVG Volume (30 Days)
2.3M
436.6K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
24.34
EPS
N/A
N/A
Revenue
$152,159,000.00
N/A
Revenue This Year
$21.85
N/A
Revenue Next Year
$16.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
35.68
N/A
52 Week Low
$13.98
$13.64
52 Week High
$28.53
$44.28

Technical Indicators

Market Signals
Indicator
ALKT
RAPP
Relative Strength Index (RSI) 43.26 54.13
Support Level $16.10 $33.54
Resistance Level $17.81 $43.70
Average True Range (ATR) 0.80 2.88
MACD -0.13 -0.01
Stochastic Oscillator 3.76 49.05

Price Performance

Historical Comparison
ALKT
RAPP

About ALKT Alkami Technology Inc.

Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: